CY1109513T1 - Φαρμακευτικη συνθεση μικροσφαιριδιων για την προληψη του ακρωτηριασμου διαβητικου ποδιου - Google Patents

Φαρμακευτικη συνθεση μικροσφαιριδιων για την προληψη του ακρωτηριασμου διαβητικου ποδιου

Info

Publication number
CY1109513T1
CY1109513T1 CY20091101105T CY091101105T CY1109513T1 CY 1109513 T1 CY1109513 T1 CY 1109513T1 CY 20091101105 T CY20091101105 T CY 20091101105T CY 091101105 T CY091101105 T CY 091101105T CY 1109513 T1 CY1109513 T1 CY 1109513T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
microphyses
egf
prevent diabetic
diabetic health
Prior art date
Application number
CY20091101105T
Other languages
English (en)
Inventor
Rodriguez Blas Yamir Betancourt
Martínez Vivian María Sáez
Meireles Rolando Páez
Acosta Jorge Amador Berlanga
Hernández José Ángel Ramón
Cuba
Original Assignee
Centro De Ingenieria Genetica Y Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38185604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109513(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro De Ingenieria Genetica Y Biotecnologia filed Critical Centro De Ingenieria Genetica Y Biotecnologia
Publication of CY1109513T1 publication Critical patent/CY1109513T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

Η παρούσα εφεύρεση σχετίζεται με φαρμακευτική σύνθεση η οποία περιλαμβάνει πολυμερικά μικροσφαιρίδα που περιέχουν επιδερμικό αυξητικό παράγοντα (EGF) για εφαρμογή, μέσω της παρεντερικής οδού, στα κάτω άκρα διαβητικών ασθενών με δερματικές χρόνιες ισχαιμικές ελκωτικές πληγές. Η φαρμακευτική σύνθεση που περιγράφεται στο κείμενο, σε αντίθεση με τη στάθμη της τεχνικής, είναι χρήσιμη διότι περιορίζει τη συχνότητα χορήγησης κατά της διάρκεια της αγωγής και επιτρέπει την επούλωση των ελκωτικών πληγών εντός χρονικού διαστήματος βραχύτερου σε σχέση με την ένεση ισοδύναμων ποσοτήτων μη εγκλεισμένου EGF.
CY20091101105T 2006-01-31 2009-10-23 Φαρμακευτικη συνθεση μικροσφαιριδιων για την προληψη του ακρωτηριασμου διαβητικου ποδιου CY1109513T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20060021A CU23388B6 (es) 2006-01-31 2006-01-31 Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
EP07702319A EP1987817B1 (en) 2006-01-31 2007-01-29 Pharmaceutical composition of microspheres for preventing diabetic foot amputation

Publications (1)

Publication Number Publication Date
CY1109513T1 true CY1109513T1 (el) 2014-08-13

Family

ID=38185604

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101105T CY1109513T1 (el) 2006-01-31 2009-10-23 Φαρμακευτικη συνθεση μικροσφαιριδιων για την προληψη του ακρωτηριασμου διαβητικου ποδιου

Country Status (24)

Country Link
US (1) US8741848B2 (el)
EP (1) EP1987817B1 (el)
JP (1) JP5219841B2 (el)
KR (1) KR101401273B1 (el)
CN (2) CN103933552A (el)
AR (1) AR059234A1 (el)
AT (1) ATE437631T1 (el)
AU (1) AU2007211753B2 (el)
BR (1) BRPI0707395A2 (el)
CA (1) CA2640743C (el)
CU (1) CU23388B6 (el)
CY (1) CY1109513T1 (el)
DE (1) DE602007001786D1 (el)
DK (1) DK1987817T3 (el)
ES (1) ES2330688T3 (el)
HK (1) HK1198743A1 (el)
MY (1) MY143742A (el)
PL (1) PL1987817T3 (el)
PT (1) PT1987817E (el)
RU (1) RU2426528C2 (el)
SG (1) SG169366A1 (el)
SI (1) SI1987817T1 (el)
WO (1) WO2007087759A2 (el)
ZA (1) ZA200806648B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23411B6 (es) * 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético
ES2340902B1 (es) 2008-07-01 2011-05-03 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas.
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
KR101156094B1 (ko) * 2010-02-22 2012-06-20 경상대학교산학협력단 약물송달을 위한 양친성 ＰＨＡ－ｍＰＥＧ 공중합 나노 컨테이너
ES2357601B1 (es) 2011-01-26 2012-03-21 Laboratorios Farmacéuticos Rovi, S.A. Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido n�?trico y su uso en tratamiento de úlceras crónicas.
EP2737895A1 (en) * 2012-11-30 2014-06-04 Praxis Pharmaceutical, S.A. Microparticles with EGF, method of preparation and use
EP2821077A1 (en) 2013-07-04 2015-01-07 Praxis Biopharma Research Institute Lipid nanoparticles for wound healing
EP3097922A1 (fr) 2015-05-28 2016-11-30 Denis Barritault Composition pour le traitement des lesions tissulaires
CN106267163A (zh) * 2015-06-09 2017-01-04 济南博创医药科技有限公司 一种治疗皮肤创伤的药物组合物及其药物制剂
MX2016016339A (es) * 2016-12-09 2018-06-08 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A S De C V Composicion coadyuvante de un factor de crecimiento y un neuropeptido para acelerar la cicatrizacion de heridas y la repitelizacion de organos.
KR102218427B1 (ko) * 2017-09-20 2021-02-22 차의과학대학교 산학협력단 단백질 약물을 포함하는 코아세르베이트 조성물 및 이를 포함하는 창상 치료제
CU20190022A7 (es) * 2019-03-18 2020-10-20 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica para el tratamiento de la úlcera del pie diabético

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5034375A (en) 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
AU633078B2 (en) 1989-04-04 1993-01-21 Alcon Laboratories, Inc. The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
WO1991001719A1 (en) 1989-08-01 1991-02-21 The University Of Michigan Topical delivery of peptides/proteins entrapped in dehydration/rehydration liposomes
AU629316B2 (en) * 1990-04-11 1992-10-01 Flora Inc. Periodontal disease treatment system
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
WO1997041899A1 (en) * 1996-05-03 1997-11-13 Innogenetics N.V. New medicaments containing gelatin cross-linked with oxidized polysaccharides
US5861149A (en) * 1997-06-04 1999-01-19 Polyheal Ltd. Methods for wound treatment
ES2382636T3 (es) * 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Método para producir composiciones para la administración mejorada de moléculas bioactivas
HK1077740A1 (en) 2001-12-20 2006-02-24 Ct Ingenieria Genetica Biotech Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
WO2003075949A1 (en) 2002-03-12 2003-09-18 Bio-Click Technologies Ltd. Method and composition for treating skin wounds with epidermal growth factor
CN1720989A (zh) * 2004-07-15 2006-01-18 深圳市清华源兴生物医药科技有限公司 一种表皮生长因子缓释微球及其制备方法与应用
CU23411B6 (es) 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético

Also Published As

Publication number Publication date
CU23388B6 (es) 2009-07-16
RU2008135354A (ru) 2010-03-10
CA2640743C (en) 2012-05-15
WO2007087759A3 (es) 2007-09-20
KR101401273B1 (ko) 2014-05-29
KR20080096804A (ko) 2008-11-03
SG169366A1 (en) 2011-03-30
HK1198743A1 (en) 2015-06-05
JP5219841B2 (ja) 2013-06-26
AU2007211753B2 (en) 2012-03-01
ZA200806648B (en) 2009-05-27
ATE437631T1 (de) 2009-08-15
EP1987817B1 (en) 2009-07-29
JP2009525288A (ja) 2009-07-09
US8741848B2 (en) 2014-06-03
DK1987817T3 (da) 2009-11-30
DE602007001786D1 (de) 2009-09-10
EP1987817A2 (en) 2008-11-05
BRPI0707395A2 (pt) 2011-05-03
PT1987817E (pt) 2009-10-26
CN101400338A (zh) 2009-04-01
SI1987817T1 (sl) 2009-12-31
MY143742A (en) 2011-07-15
WO2007087759A2 (es) 2007-08-09
ES2330688T3 (es) 2009-12-14
US20090220608A1 (en) 2009-09-03
CN103933552A (zh) 2014-07-23
PL1987817T3 (pl) 2010-01-29
AR059234A1 (es) 2008-03-19
AU2007211753A1 (en) 2007-08-09
CA2640743A1 (en) 2007-08-09
RU2426528C2 (ru) 2011-08-20

Similar Documents

Publication Publication Date Title
CY1109513T1 (el) Φαρμακευτικη συνθεση μικροσφαιριδιων για την προληψη του ακρωτηριασμου διαβητικου ποδιου
CY1121125T1 (el) Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης
EA201170651A1 (ru) Композиция для окислительного фотоактивируемого омоложения кожи, содержащая гиалуроновую кислоту, глюкозамин или аллантоин
CY1118821T1 (el) Γελες με βαση υαλουρονικο οξυ οι οποιες περιλαμβανουν αναισθητικους παραγοντες
CY1117770T1 (el) Διαδερμικο θεραπευτικο συστημα για χορηγηση της δραστικης ουσιας βουπρενορφινη
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
CY1116485T1 (el) Χρηση ουλιπρισταλης στην αγωγη εναντι ινομυωματων της μητρας
UA111162C2 (uk) Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
CR20110198A (es) Fijación de modo en el dominio de fourier
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
DE602006016058D1 (de) Vorrichtungen zur Behandlung von empfänglicher Plaque
DE602006008280D1 (de) Verbesserungen im zusammenhang mit hautverbänden
ATE477758T1 (de) Einweg-vorrichtung zur behandlung von infektionen der menschlichen extremitäten
CY1111903T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση
AR046690A1 (es) Composiciones de adn estabilizado para recubrir microproyecciones
BRPI0916985A2 (pt) composto de tetraciclina c7-fluoro substituído, composição farmacêutica que o compreende e método para o tratamento ou prevenção de uma infecção ou colonização em um paciente
CY1120193T1 (el) Μεθοδοι θεραπειας συμφυτικης θυλακιτιδας
WO2008130607A3 (en) Wound healing compositions containing keratin biomaterials
AR078736A1 (es) Una solucion de droga de taxanos que comprende un regulador de ph y su metodo de preparacion
WO2006135493A3 (en) A composition for wound healing and use thereof
NZ601559A (en) Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
RU2014124987A (ru) Гиалуроновая кислота и ее применение в лечении венозной недостаточности и варикозного расширения вен
CY1108991T1 (el) Μεθοδος επουλωσης τραυματων με τη χορηγηση ανθρωπινης il-18
EA201991280A1 (ru) Антисептическая композиция, содержащая унитиол и диметилсульфоксид, применение такой композиции и способ обработки ран с ее использованием
WO2014186075A3 (en) Modulation of heparin-binding epidermal growth factor activity for tympanic membrane healing